BeyondSpring Inc. (BYSI)
$1.56
Rating:
Recommendation:
Strong Buy
| Symbol | BYSI |
|---|---|
| Price | $1.56 |
| Beta | 1.198 |
| Volume Avg. | 0.37M |
| Market Cap | 60.729M |
| Shares () | - |
| 52 Week Range | 1.13-33.0 |
| 1y Target Est | - |
| DCF Unlevered | BYSI DCF -> | |
|---|---|---|
| DCF Levered | BYSI LDCF -> | |
| ROE | -133.13% | Strong Sell |
| ROA | -78.60% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 227.57% | Strong Buy |
| P/E | - | |
| P/B | 2.28 | Strong Buy |
Latest BYSI news
About
Download (Excel)BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.